Advertisement

Affibody-mediated tumour targeting of HER-2 expressing xenografts in mice

  • Ann-Charlott SteffenEmail author
  • Anna Orlova
  • Maria Wikman
  • Fredrik Y. Nilsson
  • Stefan Ståhl
  • Gregory P. Adams
  • Vladimir Tolmachev
  • Jörgen Carlsson
Original article

Abstract

Purpose

Targeted delivery of radionuclides for diagnostic and therapeutic applications has until recently largely been limited to receptor ligands, antibodies and antibody-derived molecules. Here, we present a new type of molecule, a 15-kDa bivalent affibody called (ZHER2:4)2, with potential for such applications. The (ZHER2:4)2 affibody showed high apparent affinity (K D=3 nM) towards the oncogene product HER-2 (also called p185/neu or c-erbB-2), which is often overexpressed in breast and ovarian cancers. The purpose of this study was to investigate the in vivo properties of the new targeting agent.

Methods

The biodistribution and tumour uptake of the radioiodinated (ZHER2:4)2 affibody was studied in nude mice carrying tumours from xenografted HER-2 overexpressing SKOV-3 cells.

Results

The radioiodinated (ZHER2:4)2 affibody was primarily excreted through the kidneys, and significant amounts of radioactivity were specifically targeted to the tumours. The blood-borne radioactivity was, at all times, mainly in the macromolecular fraction. A tumour-to-blood ratio of about 10:1 was obtained 8 h post injection, and the tumours could be easily visualised with a gamma camera at this time point.

Conclusion

The results indicate that the (ZHER2:4)2 affibody is an interesting candidate for applications in nuclear medicine, such as radionuclide-based tumour imaging and therapy.

Keywords

Affibody HER-2 Imaging SKOV-3 Tumour 

Notes

Acknowledgements

The authors thank Charles Widström at the department of Nuclear Medicine at Uppsala University Hospital for help with the gamma camera. Thanks also to Kenneth Wester and Veronika Asplund Eriksson for help with the immunohistochemistry, autoradiography and photographic procedures. The work was financially supported by grant no 0980-B04-17XCC (040171) from the Swedish Cancer Society.

References

  1. 1.
    Scholl S, Beuzeboc P, Pouillart P. Targeting HER2 in other tumor types. Ann Oncol 2001;12 Suppl 1:S81–7PubMedCrossRefGoogle Scholar
  2. 2.
    Berchuck A, Kamel A, Whitaker R, Kerns B, Olt G, Kinney R, et al. Overexpression of HER-2/neu is associated with poor survival in advanced epithelial ovarian cancer. Cancer Res 1990;50:4087–91PubMedGoogle Scholar
  3. 3.
    Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987;235:177–82PubMedCrossRefGoogle Scholar
  4. 4.
    Carlomagno C, Perrone F, Gallo C, De Laurentiis M, Lauria R, Morabito A, et al. c-erb B2 overexpression decreases the benefit of adjuvant tamoxifen in early-stage breast cancer without axillary lymph node metastases. J Clin Oncol 1996;14:2702–8PubMedGoogle Scholar
  5. 5.
    Carlsson J, Nordgren H, Sjostrom J, Wester K, Villman K, Bengtsson NO, et al. HER2 expression in breast cancer primary tumours and corresponding metastases. Original data and literature review. Br J Cancer 2004;90:2344–8.PubMedGoogle Scholar
  6. 6.
    Press MF, Cordon-Cardo C, Slamon DJ. Expression of the HER-2/neu proto-oncogene in normal human adult and fetal tissues. Oncogene 1990;5:953–62PubMedGoogle Scholar
  7. 7.
    Natali PG, Nicotra MR, Bigotti A, Venturo I, Slamon DJ, Fendly BM, et al. Expression of the p185 encoded by HER2 oncogene in normal and transformed human tissues. Int J Cancer 1990;45:457–61PubMedCrossRefGoogle Scholar
  8. 8.
    Klapper LN, Glathe S, Vaisman N, Hynes NE, Andrews GC, Sela M, et al. The ErbB-2/HER2 oncoprotein of human carcinomas may function solely as a shared coreceptor for multiple stroma-derived growth factors. Proc Natl Acad Sci U S A 1999;96:4995–5000PubMedCrossRefGoogle Scholar
  9. 9.
    Yarden Y, Sliwkowski MX. Untangling the ErbB signalling network. Nat Rev Mol Cell Biol 2001;2:127–37.PubMedCrossRefGoogle Scholar
  10. 10.
    Beaumier PL, Krohn KA, Carrasquillo JA, Eary J, Hellstrom I, Hellstrom KE, et al. Melanoma localization in nude mice with monoclonal Fab against p97. J Nucl Med 1985;26:1172–9PubMedGoogle Scholar
  11. 11.
    Hu S, Shively L, Raubitschek A, Sherman M, Williams LE, Wong JY, et al. Minibody: a novel engineered anti-carcinoembryonic antigen antibody fragment (single-chain Fv-CH3) which exhibits rapid, high-level targeting of xenografts. Cancer Res 1996;56:3055–61PubMedGoogle Scholar
  12. 12.
    Schier R, Marks JD, Wolf EJ, Apell G, Wong C, McCartney JE, et al. In vitro and in vivo characterization of a human anti-c-erbB-2 single-chain Fv isolated from a filamentous phage antibody library. Immunotechnology 1995;1:73–81PubMedCrossRefGoogle Scholar
  13. 13.
    Nord K, Gunneriusson E, Ringdahl J, Stahl S, Uhlen M, Nygren PA. Binding proteins selected from combinatorial libraries of an alpha-helical bacterial receptor domain. Nat Biotechnol 1997;15:772–7PubMedCrossRefGoogle Scholar
  14. 14.
    Wikman M, Steffen AC, Gunneriusson E, Tolmachev V, Adams GP, Carlsson J, et al. Selection and characterization of HER2/neu-binding affibody ligands. Protein Eng Des Sel 2004;17:455–62PubMedCrossRefGoogle Scholar
  15. 15.
    Gunneriusson E, Nord K, Uhlen M, Nygren P. Affinity maturation of a Taq DNA polymerase specific affibody by helix shuffling. Protein Eng 1999;12:873–8PubMedCrossRefGoogle Scholar
  16. 16.
    Steffen AC, Wikman M, Tolmachev V, Adams GP, Nilsson FY, Ståhl S, et al. In vitro characterization of a bivalent anti-HER-2 affibody with potential for radionuclide-based diagnostics.Cancer Biother Radiopharm 2005; 20:239–48PubMedCrossRefGoogle Scholar
  17. 17.
    Wester K, Asplund A, Backvall H, Micke P, Derveniece A, Hartmane I, et al. Zinc-based fixative improves preservation of genomic DNA and proteins in histoprocessing of human tissues. Lab Invest 2003;83:889–99PubMedGoogle Scholar
  18. 18.
    Adams GP, Schier R, McCall AM, Crawford RS, Wolf EJ, Weiner LM, et al. Prolonged in vivo tumour retention of a human diabody targeting the extracellular domain of human HER2/neu. Br J Cancer 1998;77:1405–12PubMedGoogle Scholar
  19. 19.
    Adams GP, Schier R, McCall AM, Simmons HH, Horak EM, Alpaugh RK, et al. High affinity restricts the localization and tumor penetration of single-chain fv antibody molecules. Cancer Res 2001;61:4750–5PubMedGoogle Scholar
  20. 20.
    Adams GP. Improving the tumor specificity and retention of antibody-based molecules. In Vivo 1998;12:11–21PubMedGoogle Scholar
  21. 21.
    Mogensen CE, Solling. Studies on renal tubular protein reabsorption: partial and near complete inhibition by certain amino acids. Scand J Clin Lab Invest 1977;37:477–86PubMedCrossRefGoogle Scholar
  22. 22.
    Bernard A, Ouled Amor A, Lauwerys R. Charge-dependent renal uptake of beta 2-microglobulin in conscious rats. Scand J Clin Lab Invest 1992;52:415–23PubMedCrossRefGoogle Scholar
  23. 23.
    Huston JS, George AJ, Adams GP, Stafford WF, Jamar F, Tai MS, et al. Single-chain Fv radioimmunotargeting. Q J Nucl Med 1996;40:320–33PubMedGoogle Scholar
  24. 24.
    Carlsson J, Forssell Aronsson E, Hietala SO, Stigbrand T, Tennvall J. Tumour therapy with radionuclides: assessment of progress and problems. Radiother Oncol 2003;66:107–17PubMedCrossRefGoogle Scholar
  25. 25.
    Weinstein JN, Eger RR, Covell DG, Black CD, Mulshine J, Carrasquillo JA, et al. The pharmacology of monoclonal antibodies. Ann N Y Acad Sci 1987;507:199–210PubMedCrossRefGoogle Scholar
  26. 26.
    Fujimori K, Covell DG, Fletcher JE, Weinstein JN. Modeling analysis of the global and microscopic distribution of immunoglobulin G, F(ab')2, and Fab in tumors. Cancer Res 1989;49:5656–63PubMedGoogle Scholar
  27. 27.
    Lindstrom A, Carlsson J. Penetration and binding of epidermal growth factor-dextran conjugates in spheroids of human glioma origin. Cancer Biother 1993;8:145–58PubMedGoogle Scholar
  28. 28.
    Tolmachev V, Orlova A, Lundqvist H. Approaches to improve cellular retention of radiohalogen labels delivered by internalising tumour-targeting proteins and peptides. Curr Med Chem 2003;10:2447–60PubMedCrossRefGoogle Scholar
  29. 29.
    Sundberg AL, Blomquist E, Carlsson J, Steffen AC, Gedda L. Cellular retention of radioactivity and increased radiation dose. Model experiments with EGF-dextran. Nucl Med Biol 2003;30:303–15PubMedCrossRefGoogle Scholar
  30. 30.
    Mattes MJ, Griffiths GL, Diril H, Goldenberg DM, Ong GL, Shih LB. Processing of antibody-radioisotope conjugates after binding to the surface of tumor cells. Cancer 1994;73:787–93.PubMedCrossRefGoogle Scholar
  31. 31.
    Motta-Hennessy C, Sharkey RM, Goldenberg DM. Metabolism of indium-111-labeled murine monoclonal antibody in tumor and normal tissue of the athymic mouse. J Nucl Med 1990;31:1510–9PubMedGoogle Scholar
  32. 32.
    Shih LB, Thorpe SR, Griffiths GL, Diril H, Ong GL, Hansen HJ, et al. The processing and fate of antibodies and their radiolabels bound to the surface of tumor cells in vitro: a comparison of nine radiolabels. J Nucl Med 1994;35:899–908PubMedGoogle Scholar

Copyright information

© Springer-Verlag 2006

Authors and Affiliations

  • Ann-Charlott Steffen
    • 1
    Email author
  • Anna Orlova
    • 2
  • Maria Wikman
    • 3
  • Fredrik Y. Nilsson
    • 1
    • 2
  • Stefan Ståhl
    • 3
  • Gregory P. Adams
    • 4
  • Vladimir Tolmachev
    • 1
  • Jörgen Carlsson
    • 1
  1. 1.Department of Oncology, Radiology and Clinical Immunology, Rudbeck LaboratoryUppsala UniversityUppsalaSweden
  2. 2.Affibody ABBrommaSweden
  3. 3.Department of Molecular BiotechnologyAlbaNova University Center, Royal Institute of Technology (KTH)StockholmSweden
  4. 4.Department of Medical OncologyFox Chase Cancer CenterPhiladelphiaUSA

Personalised recommendations